Oncocross

382150· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩2,905+1.04%

2026-11-02

Financials

Valuation Metrics

Oncocross's Market Cap is ₩379B. At end of 2025 it was ₩1250B. Ranked #1884 of 2,405 in KR market (top 78%), #1168 of 1,627 on KOSDAQ (top 72%), #200 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 87%) by Market Cap.

Investment Metrics(as of 2026-11-02)

Metric	Value	Rank
Size
Market Cap	37.90B KRW	KR#1,884/2,405 Sec#200/231
Revenue	395.5M KRW	KR#2,375/2,405 Sec#221/231
Net Income	-6.54B KRW	KR—/2,405 Sec—/231
Total Assets	32.32B KRW	KR#2,312/2,405 Sec#219/231
Net Assets	13.56B KRW	KR#2,336/2,405 Sec#221/231
Employees	31	KR#2,187/2,405 Sec#205/231
Value
P/B	2.79x	KR#2,114/2,405 Sec#169/231
P/S	95.83x	KR#2,378/2,405 Sec#211/231
Profitability
ROE	-48.21%	KR#2,259/2,405 Sec#194/231
ROA	-20.23%	KR#2,233/2,405 Sec#177/231
Op. Margin	-2474.30%	KR#2,371/2,405 Sec#221/231
Revenue Growth	-61.91%	KR#2,294/2,405 Sec#207/231
Financial Health
Debt Ratio	138.33%	KR#1,835/2,405 Sec#203/231
Total Debt	8.61B KRW	KR#1,663/2,405 Sec#151/231
Cash	284.9M KRW	KR#2,358/2,405 Sec#226/231
Current Ratio	1.44x	KR#1,250/2,405 Sec#134/231
Performance
1Y Return	-64.49%	KR#2,224/2,405 Sec#211/231
1M Return	-22.94%	KR#2,009/2,405 Sec#199/231
From 52W High	-79.95%	KR#2,285/2,405 Sec#209/231
1Y MDD	-80.64%	KR#2,285/2,405 Sec#203/231
Trading
Volume	10,988 shares	KR#1,800/2,405 Sec#174/231
Trading Value	31.8M KRW	KR#1,937/2,405 Sec#202/231
Foreign Own.	1.69%	KR#1,750/2,405 Sec#169/231
Per Share
EPS	-501 KRW	KR—/2,405 Sec—/231
BPS	1,040 KRW	KR#2,294/2,405 Sec#210/231

Company Info

CEO 김이랑, 강지훈 (각자대표)

Employees 31

Founded 2015

HQ 서울특별시 송파구, KR

Website www.oncocross.com/

동사는 2015년 설립되어 2024년 코스닥시장에 기술성장기업으로 상장한 중소·벤처기업임. AI 기반 신약개발 플랫폼 RAPTOR AI, ONCO-RAPTOR AI, ONCOfind AI를 개발하여 적응증 발굴, 병용약물 스크리닝, 치료 타겟 탐색 서비스를 제공함. 전통적 신약개발의 장기 소요와 높은 실패율 문제를 AI 기반 전사체 데이터 분석으로 해결하여 임상 성공 확률을 높이고 R&D 생산성을 개선하는 혁신을 추구하고 있음. 온코크로스는 2015년에 설립되었으며 서울특별시 송파구에 본사를 두고 있습니다.